Non-Small Cell Lung Cancer: Evolution into Immunotherapies.
By Hardik Patel, Lead Analyst
19 October 2015
I am Lead Analyst for oncology at Datamonitor Healthcare, based in the New York office. I have a Bachelor of Science deg...
Read full bio
Immunotherapies are one of the fastest growing treatment algorithms in pharma at the moment, and non-small cell lung cancer (NSCLC) is just one area of oncology that is going to make the transition into being dominated by this type of therapy. Not only that, but this focus will help to triple the value of the NSCLC market by 2023.
Our newest infographic will allow you to explore the key events up to 2023 that will make immunotherapies a key treatment type in NSCLC, and the key players in this field.
What will you learn from this infographic?
- How PD-1/PD-L1 inhibitors is forecast to overtake EGFR inhibitors as the most commercially successful treatment type in NSCLC
- Which of the five PD-1/PD-L1 inhibitors set to launch by 2023 is forecast to lead the ways in sales and why?
- The key launch dates of immunotherapies over the next four years you’ll need to look out for
Download the infographic by filling out the form now >>
Posted in Oncology.